Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 3361979

BEQUIV interactive microcomputer program for testing equivalence in two-group comparative bioavailability trials.

M Durisová·T Trnovec
View original source ↗Export metadata ↓

Abstract

The BEQUIV program, written in the BASIC language, employs an algorithm based on the Anderson and Hauck approach for testing equivalence in two-group comparative bioavailability trials (7). Options for calculation of basic statistical parameters and analysis of variance were included in view of the maximal flexibility of the program. Performance of the program was demonstrated by means of a numerical example taken from the pharmacokinetic literature. The program is designed for the non-statistically trained user.

Explore related subjects

Biological AvailabilityHumansModels, BiologicalSoftwareTherapeutic EquivalencyComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Durisová, T Trnovec. 1988. BEQUIV interactive microcomputer program for testing equivalence in two-group comparative bioavailability trials.. https://pubmed.ncbi.nlm.nih.gov/3361979/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

[Original brands and generic preparations].

BACKGROUND: Modern guidelines of drug approval aim at interchangeability of drugs containing the same active ingredients. Therapeutic equivalence of original and generic drugs is assumed as soon as bioequivalence is documented. For this to be accepted, first, pharmaceutical equivalence must prevail (the same amount of active substances in the same dosage forms) and, second, differences in bioavailabilities must not exceed certain limits. Drastic deviations from the original--not infrequent in the past--have become rare under the new sets of rules. CURRENT RELEVANCE: However, there is still room for sometimes stunning discrepancies between approved drugs, since the current procedures--mainly for economic reasons--do not cover some potentially relevant aspects: Usually, studies are performed on young, healthy, mostly male volunteers; possible effects of meals on bioavailability are not investigated and, after approval of a drug, maintenance of attested quality--as with all manufacturers--is not monitored. Moreover, the tolerated deviations from the bioavailability of the original drug are quite large; with certain substances, a change from the generic drug with the lowest bioavailability to that with the highest could mean transition from low efficacy to a toxic dose level. Documented examples include carbamazepine, phenytoin, levothyroxin, verapamil, and aspirin. CONCLUSIONS: In conclusion, even today's sophisticated rules do not suffice to cover all eventualities. In particular, drugs with a narrow therapeutic range require close scrutiny in product selection. Pertinent are drug documentation as well as the distinguishing features of the respective manufacturers, mainly scientific support and record of product reliability. Besides the sometimes insufficient official documentation, the internet has been gaining importance as a source of information.

Biological Availability↗
PubMed2000

Dietary folate equivalents: interpretation and application.

The 1998 Dietary Reference Intakes express the new Recommended Dietary Allowances for folate in dietary folate equivalents ("DFEs"), which account for differences in the absorption of naturally occurring food folate and the more bioavailable synthetic folic acid. The quantity of dietary folate equivalents occurring naturally in food equals the micrograms of folate as reported, and the dietary folate equivalents provided by fortified foods equal the micrograms of food folate plus 1.7 times the micrograms of added folic acid. Currently, the use of dietary folate equivalents is recommended for planning and evaluating the adequacy of people's folate intake. As a result of new US Food and Drug Administration regulations, folic acid has been added to enriched cereal grains and thus affects hundreds of food products. To help dietetics professionals plan and evaluate diets that include enriched cereal grain products, we estimated the dietary folate equivalent content of a selection of foods using data supplied by the US Department of Agriculture and grouped the foods by dietary folate equivalent content.

Biological Availability↗